Roivant joins RNA splicing push with Eisai deal
pharmaphorum
JANUARY 6, 2022
Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.
Let's personalize your content